Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
See how to make money instead of spending it on Black Friday with this offer (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
See how to make money instead of spending it on Black Friday with this offer (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:NLNK

NewLink Genetics - NLNK Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$5.24
$5.53
50-Day Range
$0.89
$14.10
52-Week Range
$0.82
$3.60
Volume
10,864 shs
Average Volume
547,540 shs
Market Capitalization
$202.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NLNK stock logo

About NewLink Genetics (NASDAQ:NLNK) Stock

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

NLNK Stock News Headlines

Here's what Wall Street expects from NewLink Genetics's earnings
What Wall Street expects from NewLink Genetics's earnings
Lumos Pharma Inc
NewLink Genetics Corp (NLNK.O)
NewLink shareholders back Lumos merger
NewLink Genetics EPS beats by $0.06, beats on revenue
NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?
NewLink Hooks up with Ellipses
20 Stocks Moving in Tuesday's Pre-Market Session
4 Stocks To Watch For December 24, 2019
NewLink +16% on NLG207 license agreement
The First Ebola Vaccine Has Been Approved in the US
See More Headlines

Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

NLNK Company Calendar

Last Earnings
11/06/2019
Today
11/27/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NLNK
CUSIP
65151110
Fax
N/A
Employees
55
Year Founded
N/A

Profitability

Net Income
$-42,990,000.00
Net Margins
-4,592.84%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$940,000.00
Book Value
$2.11 per share

Miscellaneous

Free Float
N/A
Market Cap
$202.69 million
Optionable
Optionable
Beta
1.17

Key Executives

  • Dr. Charles J. Link Jr. (Age 60)
    Co-Founder, Chairman, CEO & Chief Scientific Officer
  • Mr. Nicholas N. Vahanian (Age 52)
    Co-Founder, Pres, Chief Medical Officer & Director
  • Dr. Eugene P. Kennedy M.D. (Age 50)
    FACS, Chief Medical Officer
  • Mr. Brian Wiley (Age 51)
    Chief Commercial Officer
  • Mr. Carl W. Langren (Age 64)
    CFO & Principal Accounting Officer













NLNK Stock - Frequently Asked Questions

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%.

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD).

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $5.43.

How much money does NewLink Genetics make?

NewLink Genetics (NASDAQ:NLNK) has a market capitalization of $202.69 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The official website for the company is www.newlinkgenetics.com. The biotechnology company can be reached via phone at 515-296-5555 or via email at investor@linkp.com.

This page (NASDAQ:NLNK) was last updated on 11/27/2022 by MarketBeat.com Staff